Humacyte (HUMA) Jefferies 2024 Global Healthcare Conference summary

Technology platform and clinical pipeline

• Developed engineered, off-the-shelf human tissues, primarily blood vessels, from a proprietary cell bank, enabling patient-specific repopulation and long-term durability.

• Lead indication is vascular trauma, with additional programs in dialysis access, peripheral artery disease, pediatric heart disease, coronary bypass, and type 1 diabetes.

• Manufacturing is highly automated, with capacity for up to 40,000 vessels per year, and has been de-risked through established clinical trial use since 2021.

• Over 600 patients treated, with more than 1,000 patient-years of exposure and no clinical rejection episodes.

Regulatory and clinical milestones

• FDA granted priority review for the Biologics License Application (BLA) in traumatic injury; PDUFA date set for August 10.

• BLA supported by combined data from U.S. and Ukraine trauma trials, showing 91.5% patency at 30 days and significantly lower infection and amputation rates compared to synthetic grafts.

• Phase III trial in dialysis access (V007) completed enrollment; top-line results expected in Q3.

• Partnerships with Mayo Clinic, Fresenius Medical Care, and U.S. Department of Defense, with the latter naming the vessel a top 5 priority for FDA approval.

Commercialization and market strategy

• Initial U.S. launch targets 200 Level I trauma centers, covering 80% of the trauma market with fewer than 20 sales representatives.

• Budget impact model suggests higher acquisition cost (~$25,000 per vessel) is offset by reduced infections, amputations, and long-term costs.

• Surgeons treating trauma are the same as those treating dialysis and PAD, facilitating cross-indication adoption.

• Manufacturing facility in North Carolina supports scalable production and rapid commercial ramp-up.